Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ebola vaccine trial temporarily halted
Injection
A clinical trial of an Ebola vaccine has been temporarily halted after some patients complained of fever and muscle pain.

Volunteers complain of fever and muscle pain

A clinical trial of an Ebola vaccine has been temporarily halted as a precautionary measure after four patients complained of fever and muscle pain, the University of Geneva announced on Thursday (December 11).

In a statement, the hospital said: "All of these volunteers are in good health and are being monitored regularly by the team in charge of the study."

The hospital say that the reactions were expected and the participants were informed about them during the medical consultation which took place before their inclusion in the study.

The trials are set to resume again on 5 January, after checks to ensure that the joint pain symptoms in hands and feet are "benign and transient."

Scientists are racing to develop Ebola vaccines after the world's worst outbreak of the virus has killed more than 6,000 people in West Africa so far this year.

59 volunteers have been vaccinated so far in the human safety trials in Geneva, which began in November. The hospital says that initial results from the trials show that the vaccination is very well tolerated.

Similar studies are also underway in the United States, Canada, Germany and Gabon. 

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.